Reviews/Analyses

Total Page:16

File Type:pdf, Size:1020Kb

Reviews/Analyses Reviews/Analyses Medical approaches to termination of early pregnancy P.F.A. Van Look1 & M. Bygdeman2 Termination of early pregnancy by vacuum aspiration is a well-established technique. The procedure is highly effective and has a low complication rate, particularly when performed during the first few weeks after missed menses. However, this parasurgical method requires skilled health care personnel, and attempts have therefore been made to find medical alternatives. Prostaglandins were the first agents to be used successfully for this purpose, but the high incidence of mainly gastrointestinal side-effects has limited their widespread use. More recently, attention has focused on antiprogestational steroids, i.e., compounds that prevent the action of progesterone either by inhibiting its biosynthesis or by preventing it from binding to the cellular receptors in target organs. Current experience indicates that these com- pounds, particularly when used in combination with a low dose of a synthetic prostaglandin analogue, have the potential to become a safe, effective, and acceptable medical method for the termination of early pregnancy. Introduction efficacy and acceptability, as the currently employed parasurgical procedure, vacuum aspiration. Prior to The total number of legal abortions carried out examining the medical alternatives it is therefore globally each year is uncertain, but is likely to be appropriate to review briefly the performance of the 30-40 million (1). During the first 12 weeks of preg- parasurgical method. For this purpose, the dis- nancy, the uterus can be evacuated effectively by cussion of vacuum aspiration will be restricted to vacuum aspiration, and the rate of complications procedures carried out during the first 3-4 weeks that arise using this procedure is very low, particu- after missed menses (corresponding to 7-8 weeks' larly during the first few weeks after missed menses. amenorrhoea), since termination using medical However, parasurgical termination of pregnancy methods can only be used successfully during this requires skilled health care personnel, and attempts period (Fig. 1). have therefore been made to develop medical alter- For a detailed account of vacuum aspiration natives. during early pregnancy (a technique also known as Here, we review the experience gained with the mini-suction, mini-aspiration, or menstrual extrac- two medical approaches currently available: use of tion) see, for example, the review by van der Vlugt & prostaglandins and antiprogestational compounds. Piotrow (3). The latter comprise two distinct classes of drugs that have different modes of action: steroid biosynthesis inhibitors, such as epostane, and progesterone recep- Vacuum aspiration tor blockers, such as mifepristone (RU 486). Vacuum aspiration is a well-established technique In order to be clinically acceptable, it is manda- and will not be described in detail here. During the tory that any medical approach to termination of first 3-4 weeks after missed menses, it is usually per- early pregnancy is at least as good, in terms of safety, formed using a modified 50-ml syringe and a flexible plastic cannula of the type that was designed and 1 Medical Officer, Special Programme of Research, Development popularized by Karman in the late 1960s. Although and Research Training in Human Reproduction, World Health the exact design varies between manufacturers, the Organization, 1211 Geneva 27, Switzerland. Requests for reprints should be sent to cannulae generally have a blunt tip with two offset this author. apertures. Instead of a Karman syringe a number of 2 Chairman, Department of Obstetrics and Gynaecology, Karol- inska Hospital, Stockholm, Sweden. alternative suction sources can be used, such as a pre-evacuated bottle or a mechanical or electrical Reprint No. 5016. pump. In theory, neither anaesthesia nor dilatation Bulletin of the World Health Organization, 67 (5): 567-575 (1989) © World Health Organization 1989 567 P.F.A. Van Look & M. Bygdeman Fig. 1. Plot of the ability of prostaglandins to Induce Table 1: Distribution of significant Immediate com- complete abortion, by duration of amenorrhoea. plications among 12888 women who underwent mens- lW0, trual regulation by vacuum aspiratlon' 97 A\ 90 Complication No. of cases Uterine perforation Definite 3 (0.02)b so 81 \ Suspected 1 (0.01) Cervical laceration Sutured 2 (0.02) 70 199 Not sutured 5 (0.04) \ Blood loss (>100 ml) 51 (0.40) Shock 25 (0.19) ;ai 60 \I c Fever (> 38°C) 19 (0.15) 0 .t Pelvic infection 1 (0.01) -850 l Apnoea 2 (0.01) I CL Total 109 (0.85) E 40 8 39 See reference 5. b Figures in parentheses are percentages. 30 in the above-mentioned IFRP survey was 0.85% 20 (Table 1). Excessive bleeding, defined as a loss of more than 100 ml blood, accounted for slightly less 10 a than half of the immediate complication rate. i In the IFRP survey, delayed complications, . i.e., those that occurred more than 24 hours after 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 the evacuation but within a 6-week period, were re- Weeks since last menstrual period ported for 399 (3.53%) of the 11309 women who were followed up. Failed procedures, fever that of the cervix are required, although local anaesthesia required antibiotics, pelvic infection, or bleeding that is often used to minimize vasovagal symptoms, and required curettage (including incomplete abortions) mechanical dilatation of the cervix may be necessary were the most common delayed complications and in some women. The reported effectiveness of the procedure is occurred in about equal proportions (Table 2). A total of 508 significant, immediate or delayed com- high, with failure rates (i.e., the proportion of women plications were observed in the survey among the who require a repeat evacuation because of incom- 12888 women who underwent the procedure. This plete abortion or continuing pregnancy) of around represents a 3.94% overall complication rate if it is 2-6% (3-6). In a survey conducted by the Interna- assumed that the 1579 women (12.25%) who were tional Fertility Research Program (IFRP) between lost to follow-up did not experience a significant 1972 and 1976 in 61 clinics from 21 countries, the delayed complication. failure rate of vacuum aspiration among 11 309 women who were followed up was 1.2%, while a further 0.9% required curettage because of incom- Table 2: Distribution of significant delayed complications plete evacuation (5). In general, failure-to-terminate among 11309 women who were followed up after under- rates decrease with advancing duration of amenor- going termination of early pregnancy by vacuum aspira- rhoea and increasing experience of the individual tlon' performing the procedure. Complication No. of cases Complication rates for aspiration are low and are usually classified according to the time of their Failed proceduresb 111 (0.98)c occurrence. Immediate complications, i.e., those that Fever that required antibiotics 95 (0.84) Pelvic infection 90 (0.80) occur during the procedure itself or within 24 hours, Bleeding that required curettage 101 (0.89) include, inter alia, uterine perforation, cervical lacer- Undiagnosed ectopic pregnancy 2 (0.02) ation, excessive blood loss, shock, fever, pelvic infec- tion, and apnoea. For women who have no Total 399 (3.53) are not pre-existing medical conditions and who ' See reference 5. undergoing concurrent surgery or IUD insertion, the b Positive pregnancy test at follow-up visit. overall incidence of these immediate complications c Figures in parentheses are percentages. WHO Bulletin OMS. Vol. 67 1989 Medical approaches to termination of early pregnancy To the best of our knowledge, no systematic excessive frequency of mainly gastrointestinal side- studies have been conducted of the possible risk of effects, which precluded their routine use. The fre- late or long-term complications, i.e., those that occur quency of these side-effects can be reduced by 6 weeks or more after vacuum aspiration carried out intrauterine administration, but the clinical useful- during very early pregnancy. Such late complications ness of this approach is clearly very limited. Never- might include a tendency towards spontaneous abor- theless, these early studies were of importance since tion or prematurity in subsequent pregnancies they demonstrated the feasibility of using PGs and (which could be caused by damage to the cervix) as gave impetus to the search for analogues that have a well as acquired infertility, menstrual disorders, more selective effect on the myometrium and a rhesus immunization, or an increase in ectopic preg- greater resistance to in vivo enzymatic degradation nancies. Prospective studies, such as the investiga- by prostaglandin-15-dehydrogenase. This search has tion conducted jointly by the Royal College of been fairly successful and several analogues that are General Practitioners and the Royal College of effective when administered vaginally have been Obstetricians and Gynaecologists in the United developed (Table 3). Kingdom (7), indicate that subsequent pregnancies Among the first vaginally administered ana- are not adversely affected in women who have pre- logues to be tested clinically were 15-methyl-PGF2. viously undergone induced abortion. Since the methyl ester and 16,16-dimethyl-PGE2. For both of majority of women in these studies had their preg- these compounds, the frequency of complete abor- nancy terminated at more advanced stages of gesta- tions was satisfactory, but neither was appropriate tion, it seems reasonable to assume that vacuum for routine clinical use. In particular, for the PGF2. aspiration performed during the first 3-4 weeks after analogue the incidence of gastrointestinal side- missed menses is unlikely to have an adverse effect effects, although lower than that of the natural PGs, on the outcome of subsequent pregnancies. was still too high, whereas the PGE2 analogue was There is also no evidence that induced abortion, not stable in the suppository base. when properly performed, carries an increased risk More recently, PGE analogues have been devel- of secondary infertility.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Twenty-Week Bans, New Medical Evidence, and the Effect on Current United States Supreme Court Abortion Law Precedent Shea Leigh Line
    Idaho Law Review Volume 50 | Number 3 Article 5 October 2014 Twenty-Week Bans, New Medical Evidence, and the Effect on Current United States Supreme Court Abortion Law Precedent Shea Leigh Line Follow this and additional works at: https://digitalcommons.law.uidaho.edu/idaho-law-review Recommended Citation Shea L. Line, Twenty-Week Bans, New Medical Evidence, and the Effect on Current United States Supreme Court Abortion Law Precedent, 50 Idaho L. Rev. 139 (2014). Available at: https://digitalcommons.law.uidaho.edu/idaho-law-review/vol50/iss3/5 This Article is brought to you for free and open access by Digital Commons @ UIdaho Law. It has been accepted for inclusion in Idaho Law Review by an authorized editor of Digital Commons @ UIdaho Law. For more information, please contact [email protected]. TWENTY-WEEK BANS, NEW MEDICAL EVIDENCE, AND THE EFFECT ON CURRENT UNITED STATES SUPREME COURT ABORTION LAW PRECEDENT TABLE OF CONTENTS PART I: INTRODUCTION .................................................................. 140 PART II: ABORTION LAW PRECEDENT THROUGHOUT THE PAST FORTY YEARS: ROE V. WADE, PLANNED PARENTHOOD V. CASEY, & GONZALES V. CARHART ...... 143 A. Roe v. Wade ............................................................................. 144 B. Planned Parenthood v. Casey ................................................ 148 C. Gonzales v. Carhart ................................................................ 152 PART III: THE IMPACT OF CURRENT SUPREME COURT ABORTION LAW PRECEDENT ON THE STATES TWENTY-WEEK BANS ............................................................
    [Show full text]
  • Parental Consent Form for a Minor Seeking Abortion
    Parental Consent Form for a Minor Seeking Abortion Parental Statement: I certify that I, ___________________________, am the parent of _________________________________ (name of parent) (minor daughter name) and give consent for ____________________________ to perform an abortion on my daughter. I understand (physician name) that any person who knowingly makes a fraudulent statement in this regard commits a felony. Date: , 20 . Signature of Parent/Managing Conservator/Guardian I certify I have witnessed the execution of this consent by the parent. Subscribed and sworn to before me on this day of 20 (day) (month) Seal NOTARY PUBLIC in and for The State of OKLAHOMA My commission expires: Required attachments: - Copy of government-issued proof of identification - Written documentation that establishes that he or she is the lawful parent of the pregnant female Physician Statement: I, ____________________________, certify that according to my best information and belief, a reasonable person under (Physician name) similar circumstances would rely on the information presented by both the minor and her parent as sufficient evidence of identity. Date: , 20 . Signature of Physician ___________ (Parent Initials) Oklahoma State Department of Health 11/2013 Health Care Information Page 1 of 9 Consent of a Minor & Parental Consent Statement The law of the State of Oklahoma (Title 63, Section 1-740.13) requires physicians to obtain the consent of the minor and parent using this form prior to performing an abortion on a minor who is not emancipated.
    [Show full text]
  • Coordination Des Syndicats CGT
    Coordination des syndicats CGT STRATEGIE DE LA DIRECTION DU GROUPE SANOFI CONSEQUENCES INDUSTRIELLES ET SOCIALES Document d’août 2014 1. Situation économique – Coût du capital p2 2. Evolution des effectifs – Bilan des restructurations majeures p3 3. Stratégie Sanofi 2009-2015 : Désengagement scientifique et industriel en Europe et plus particulièrement en France p4 4. Stratégie de structuration du groupe en entités qui peuvent être cédées, vendues, fermées, échangées. p6 5. Crédit d’impôt – Des aides publiques pour quel usage ? p7 6. Industrie pharmaceutique : des besoins fondamentaux p7 7. Interpellation des élus et du gouvernement p8 1. Situation économique – Coût du capital Première entreprise pharmaceutique française et européenne. Sanofi est issu de la fusion de nombreux laboratoires pharmaceutiques français dont les principaux étaient Roussel Uclaf, Rhône Poulenc, Synthelabo, Sanofi et de l’allemand Hoechst. Sanofi représente 30 à 40% du potentiel national (effectifs, sites, R&D,…) de l’industrie pharmaceutique française dans notre pays. L’avenir du groupe et de ses activités en France conditionne l’avenir de l’industrie pharmaceutique française et constitue un élément incontournable de l’indépendance thérapeutique du pays. Le C.A. de sanofi dans le monde sur 2013 a atteint 33 milliards € et devrait se situer à un niveau légèrement supérieur en 2014. Plusieurs médicaments de référence étant aujourd’hui tombés dans le domaine public, le chiffre d’affaires repart à la hausse. Le résultat net des activités a été de 6,8 milliards € en 2013 et les projections sur 2014 laissent envisager une progression de 5% de celui-ci. La rentabilité est estimée par les économistes parmi les meilleures de l’industrie pharmaceutique dans le monde.
    [Show full text]
  • Induced Abortions in Minnesota January - December 2018: Report to the Legislature
    Induced Abortions in Minnesota January - December 2018: Report to the Legislature 07/01/2019 Induced Abortions in Minnesota January – December 2018 Report to the Legislature July 2019 Minnesota Department of Health Center for Health Statistics PO Box 64882 St. Paul, MN 55164-0882 651-201-5944 800-657-3900 [email protected] www.health.state.mn.us As requested by Minnesota Statute 3.197: This report cost approximately $4,000 to prepare, including staff time, printing and mailing expenses. Upon request, this material will be made available in an alternative format such as large print, Braille or audio recording. Printed on recycled paper. TABLE OF CONTENTS Introduction iii Technical Notes v Tables Table 1.1 Abortions by Month and Provider for Facilities 2 Table 1.2 Abortions by Month and Provider for Physicians 3 Table 2 Medical Specialty of Physician 6 Table 3 Type of Admission 6 Table 4 Age of Woman 7 Table 5 Marital Status of Woman 7 Table 6 Country/State Residence of Woman 8 Table 7 County of Residence for Women Residing in Minnesota 9 Table 8 Hispanic Ethnicity of Woman / Race of woman 10 Table 9 Race and Hispanic Ethnicity by Minnesota Residence 11 Table 10 Education Level of Woman 12 Table 11 Clinical Estimate of Fetal Gestational Age (grouped) 13 Table 11a Clinical Estimate of Fetal Gestational Age 14 Table 12 Prior Pregnancies 15 Table 13 Abortion Procedure 16 Table 14 Method of Disposal of Fetal Remains 17 Table 15 Payment Type and Health Insurance Coverage 18 Table 16 Reason for Abortion 19 Table 16a Other Stated Reason
    [Show full text]
  • The History of Abortion
    The History of Aboron Carole Joffe, PhD Professor, Bixby Center for Global Reproductive Health ! Abor%on as a Universal Phenomenon “There is every indication that abortion is an absolutely universal phenomenon, and that it is impossible even to construct an imaginary social system in which no woman would ever feel at least compelled to abort.” Devereux, A typological study of abortion in 350 primitive, ancient and pre- industrial societies, 1954. ! Early References to Abor%on SpeciCic (non-critical) references to abortion • One of earliest known medical texts, attributed to the Chinese emperor, Shen Nung, 2737-2698 B.C. • Ebers Papyrus of Egypt, 1550 B.C.-1500 B.C. • Various writers of Roman Empire: Ovid, Juvenal, Seneca, (1st century B.C., 1st and 2nd centuries A.D.) • Al-Rasi, Persian physician, 10th century Riddle, Contraception and Abortion from the Ancient World to the Renaissance, 1992. Himes, Medical History of Contraception, 1936. ! Hippocrates and Abor%on What did his oath actually say? • Translation A: “”Neither will I give a woman means to procure an abortion.” • Translation B: “Neither will I give a suppository to cause an abortion.” – i.e. Hippocrates only opposing one method of abortion Evidence supporting Translation B: “Works ascribed to Hippocrates describe a graduated set of dilators that could be used for abortions.” Joffe in Paul, et al., Management of Unintended and Abnormal Pregnancy, 2009. Riddle, Contraception and Abortion from the Ancient World to the Renaissance, 1992. ! 1950s and Beyond Gradual liberalization • China, most European countries; U.S. and Canada, India, S. Africa, Mexico City, Colombia • “menstrual extraction clinics” in Bangladesh and elsewhere ! 1950s and Beyond Gradual improvement in technology • vacuum aspiration – introduced in U.S.
    [Show full text]
  • Steps for Performing Manual Vacuum Aspiration (MVA) Using the Ipas MVA Plus® and Ipas Easygrip® Cannulae
    Steps for Performing Manual Vacuum Aspiration (MVA) Using the Ipas MVA Plus® and Ipas EasyGrip® Cannulae Step One: Prepare the Patient Step Six: Prepare the Aspirator • Administer pain medication before the • Position the plunger all the way inside procedure to have maximum effect when the the cylinder. procedure begins. • Have collar stop in place with tabs in the • Give prophylactic antibiotics to all women, or cylinder holes. therapeutic antibiotics if indicated. • Push valve buttons down and forward • Ask the woman to empty her bladder. until they lock (1). • Conduct a bimanual exam to confirm uterine • Pull plunger back until arms snap size and position. outward and catch on cylinder base (2). • Insert speculum and observe for signs of infection, bleeding or incomplete abortion. Step Seven: Suction Uterine Contents • Attach the prepared aspirator to the cannula. Step Two: Perform Cervical • Release the vacuum by Antiseptic Prep pressing both buttons. • Use antiseptic-soaked sponge to clean • Evacuate the contents of the cervical os. Start at os and spiral outward uterus by gently and slowly without retracing areas. Repeat until os has rotating the cannula 180° been completely covered by antiseptic. in each direction, using an in-and-out motion. • When the procedure is finished, depress the buttons and disconnect the cannula from the aspirator. Alternatively, withdraw the cannula and Step Three: Perform Paracervical Block aspirator without depressing the buttons. • Paracervical block is required prior to MVA. • Perform paracervical block with Signs that indicate the uterus is empty: 20cc of 1% lidocaine, or 10cc • Red or pink foam without tissue is seen passing through the cannula.
    [Show full text]
  • Ce Que Sanofi Dit De La Politique Industrielle Française
    Ce que Sanofi dit de la politique industrielle française mediapart.fr/journal/economie/030221/ce-que-sanofi-dit-de-la-politique-industrielle-francaise Martine Orange, Mediapart, 3 février 2021 Les salariés de Sanofi ont beau essayer de chercher des explications, ils ne comprennent pas. Ou plutôt ils ne comprennent que trop bien la conduite du groupe pharmaceutique. Après le revers de sa stratégie dans l’élaboration d’un vaccin contre le Covid-19, repoussé désormais au mieux à la fin de l’année, tout aurait dû pousser la direction de Sanofi à s’interroger sur la pertinence de ses choix, sur la place laissée à la recherche jugée comme essentielle. Mais rien ne s’est passé. Le 28 janvier, la direction de Sanofi Recherche et Développement en France a confirmé à l’occasion d’un comité social d’entreprise (CSE) la suppression de 364 emplois en France, une mesure qui vise particulièrement l’unité de Strasbourg appelée à être transférée en région parisienne. Ce plan s’inscrit dans un programme plus large annoncé en juillet 2020. Le groupe entend supprimer 1 700 emplois en Europe dont un millier en France sur trois ans. « Mais ce n’est qu’une partie du projet Pluton, prévient Jean-Louis Perrin, délégué CGT à Montpellier. Sanofi est en train de se désindustrialiser. Toute la pharmacie de synthèse est appelée à disparaître dans le groupe. Les sites de Sisteron, Elbeuf, Vertolaye, Brindisi (Italie), Francfort (Allemagne), Haverhill (Royaume-Uni), Újpest (Hongrie) sont destinés à sortir du groupe. Au total, cela représente 3 500 emplois. » Centre de distribution de Sanofi à Val-de-Reuil.
    [Show full text]
  • Fusiones 20De 20Labo
    "Cuando los grandes se hacen gigantes" Fusiones de Laboratorios 1 INDICE PRÓLOGO……………………………………………………………………………...…….. 3 INTRODUCCIÓN: FUSIONES Y ADQUISICIONES…………………………………..….. 4 INVESTIGACIÓN Y DESARROLLO………………………………………………………. 5 LA INDUSTRIA FARMACEUTICA………………………………………………………. 16 FUSIÓN SANOFI – AVENTIS…………………………………………………………...… 20 FUSIÓN BAYER – SCHERING……………………………………………………………. 26 FUSIÓN PFIZER – WYETH……………………………………………………………….. 30 FUSIÓN MERCK & CO. – SCHERING PLOUGH…………………………………..……. 31 FUSIÓN ROCHE – GENENTECH………………………………………………………… 34 MERCADOS REGIONALES………………………………………………………….…… 40 LA INDUSTRIA FARMACÉUTICA EN LA ARGENTINA……………………...………. 42 CONCLUSIÓN……………………………………………………………………………… 49 2 PRÓLOGO Es un verdadero privilegio que hayan pensado en mí para prologar este interesante trabajo relacionado con la formación profesional de estos inquietos alumnos de la Carrera de Agentes de Propaganda Médica. Grato además, pues recrea mi participación activa en el mundo de la Industria Farmacéutica, en calidad de Asesor de la Fuerza de Ventas e Investigador Principal durante varias décadas, período que fue enriquecedor para mí y sumó un importante valor agregado a mi bagaje médico y personal. Entiendo que lo sucedido en los avances científicos y tecnológicos durante los últimos cuarenta años, ha constituido un quiebre en la Historia de la Medicina y, por lo tanto, de la Humanidad. Es por ello que veo con beneplácito que la formación de estos entusiastas jóvenes va de la mano con los cambios de planes y esquemas de estudios de los futuros médicos.
    [Show full text]
  • The Life of the Abortion Pill in the United States
    The Life of the Abortion Pill in the United States The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation The Life of the Abortion Pill in the United States (2000 Third Year Paper) Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852153 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 80 The Life of the Abortion Pill in the United States Julie A. Hogan Eleven years after mifepristone1, the drug that chemically induces abortion and hence coined the abortion pill, was approved for use in France, American women still do not have access to the drug, although women in at least ten other nations do.2 In 1988, Americans thought the Abortion Pill [was] on the Hori- zon.3 In 1993, almost five years later, American women still did not have access to the drug, although many women's hopes were raised by newspaper headlines claiming that the Door May Be Open for [the] Abortion Pill to Be Sold in [the] U.S.4 and newspaper accounts predicting that mifepristone would be available in the United States in 1996.5 In 1996, the headlines reported that the Approval of [the] Abortion Pill by the FDA [was] Likely Soon.6 Yet, mifepristone was still not available in 1999, and newspaper headlines were less optimistic about pre- 1Mifepristone is the generic name for RU-486, the designation given the drug by its French maker, Roussel-Uclaf.
    [Show full text]
  • The Complexity of Compiling Abortion Statistics
    The Complexity of Compiling Abortion Statistics JACK C. SMITH, MS SINCE LEGAL 'INDUCED ABORTION emerged as a the January 1973 Supreme Court decision concerning medical procedure, States have rapidly passed laws the Texas and Georgia (ALI) laws (2). That ruling by liberalizing abortion-the number of legal abortions the Supreme Court invalidated most of the conditions has increased more than twentyfold in 5 years (1). In and restrictions written into the abortion laws of States the United States today, approximately one legal abor- that had reformed legislation. Furthermore, the Court's tion is reported for every five live births (1). ruling also invalidated most State abortion laws, As an adjunct to new State legislation on abortion, whether old or reform, on the grounds that the per- compilation of abortion statistics by the central health missible reasons for abortion-life, health, deformity, agency of the State is usually required. The Center for rape, and incest-were too restrictive. Although report- Disease Control (CDC), in its study of the ing of all abortions was required by Georgia's ALI-type epidemiology of legal induced abortion' in the United law, reporting was not argued as a constitutional issue States since 1969, has been communicating with State before the Supreme Court and therefore was not and local health agencies during their planning, in- responded to in the Court's decision. itiating, and refining of abortion reporting systems ac- The 1973 Supreme Court Decision precipitated a cording to each one's State laws and health regulations. new round of legislative and court actions. These ac- This communication has brought about a broad un- tions ranged from State laws passed in the spirit of the derstanding of the difficulties encountered in compiling Supreme Court's intent to laws passed in direct statewide abortion statistics.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]